Mean age was 67 years, 77% of patient had clear-cell RCC and metastatic disease was present in 94% of patients. First-line therapy was sunitinib in 61.1% of patients followed by temsirolimus in 13%, bevacizumab plus interferon-alpha in 11.3% and sorafenib in 8.5% of patients. Treatment duration was 8 months for sunitinib, 6.7 months for sorafenib, 4.5 months for bevacizumab plus interferon-alpha and 3.2 months for temsirolimus.
In this database a total of 1000 patients with advanced or metastatic RCC will be documented. So far 622 patients are included and clearly sunitinib is the most frequent first-line therapy of metastatic RCC. However, it is somewhat surprising that sunitinib was tolerated for a longer time than the competitors in first-line therapy. Other treatment strategies are less frequent and the reasons are possibly different. Besides efficacy, side effect profile, personal experience, as well as handling and approved indications (e.g. bevacizumab plus interferon-alpha and temsirolimus are only approved for first-line therapy) have an influence on the choice of first-line therapy of metastatic RCC in Germany.
Presented by P.J. Goebell et al. at the Deutsche Gesellschaft für Urologie (DGU) - 63rd Annual Congress - September 14 - 17, 2011 - Congress Center - Hamburg, Germany
Reported for UroToday by Christian Doehn, MD, PhD, Urologikum Lubeck, Lubeck, Germany.
View Full DGU 2011 Meeting Coverage
